Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633083 | 0.83 | LMNA (0.43) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| SCHEMBL10451936 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| SCHEMBL21264081 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| SCHEMBL1716474 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| SCHEMBL2138074 | 0.80 | CYP3A4 (0.62) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| SCHEMBL5823755 | 0.79 | CYP1A2 (0.37) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| SCHEMBL5823757 | 0.79 | CYP1A2 (0.37) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| Acetic Acid SCHEMBL28906961 | 0.79 | LMNA (0.48) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| SCHEMBL7101790 | 0.79 | CYP3A4 (0.66) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 | |
| SCHEMBL261986 | 0.79 | CYP3A4 (0.66) | CYP3A4CYP2C9GRIK1RECQLAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | MEDIHELPLINE CO., LTD (KR) | 2026-05-05 | — | — | US | disclosed |
| WO-2025105415-A1 | MELANOGENESIS INHIBITOR AND EXTERNAL PREPARATION FOR SKIN CONTAINING SAME | 三菱瓦斯化学株式会社 | 2025-05-22 | — | — | WO | disclosed |
| US-20230127213-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF | PARK, OK NAM (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230103514-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF | MEDIHELPLINE CO., LTD (KR) | 2023-04-06 | — | — | US | disclosed |
| US-20230100173-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF | MEDIHELPLINE CO., LTD (KR) | 2023-03-30 | — | — | US | disclosed |
| EP-4117699-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF | Medihelpline Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| EP-4117698-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF | Medihelpline Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| EP-4117700-A1 | A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF | Medihelpline Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | CUTA, VEGFA, MMP8 | CYP3A4 3059/4885CYP2C9 2675/4885GRIK1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.